Not So Different: The Fight to Align Payer Preferences With Community Oncology
This is the third and final part of our series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.
In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced 10 research projects that will receive funding to develop innovative ways to improve biosimilar adoption in the oncology space.
For this Not So Different series, The Center for Biosimilars® is spotlighting 3 projects to improve perception of biosimilars, promote biosimilars as a therapy choice, and encourage payers to prefer biosimilar use.
In this third part, we spoke with Hong-Phuc Nguyen, PharmD, director of the pharmacy clinical network at City of Hope in Duarte, California. Dr Nguyen discussed how his project titled “Challenges to Biosimilar Adoption in Community Oncology Due to Diverse Payer Preferences for Different Biosimilars” will address how payer formulary decisions can improve or stall biosimilar uptake and acceptance.
To learn more about payer preferences, click here.
To see how Minnesota legislators are working to override payer preferences, click here.
For more on payer influence on prescribing patterns, click here.
For more on NCCN’s biosimilar work, click here.
You can also check out part 1 and part 2 of this series.
To check out our Biosimilar Approvals navigator, click here.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
November 15th 2023In part 2 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® explores a cost-effectiveness analysis evaluating the use of subcutaneous trastuzumab biosimilars to treat breast cancer in a French hospital setting.
